These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22929717)
21. Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate. Hyodo T; Kawakami J; Mikami N; Wakai H; Ishii D; Yoshida K; Iwamura M; Hida M; Kurata Y Ther Apher Dial; 2014 Jun; 18 Suppl 1():14-7. PubMed ID: 24953761 [TBL] [Abstract][Full Text] [Related]
22. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018 [TBL] [Abstract][Full Text] [Related]
23. [Use of calcium carbonate (CaCO3) as phosphate binder in dialysis patients in long-term follow-up over 3 years]. Sperschneider H; Günther K; Stein G; Marzoll I; Kirchner E Z Urol Nephrol; 1990 Aug; 83(8):449-58. PubMed ID: 2122612 [TBL] [Abstract][Full Text] [Related]
24. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662 [TBL] [Abstract][Full Text] [Related]
25. Calcium carbonate as a phosphate binder in children on continuous ambulatory peritoneal dialysis and hemodialysis. Sieniawska M; Roszkowska-Blaim M; Weglarska J; Jabłczyńska A; Welc-Dobies J Mater Med Pol; 1991; 23(3):203-8. PubMed ID: 1842716 [TBL] [Abstract][Full Text] [Related]
26. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106 [TBL] [Abstract][Full Text] [Related]
27. Sevelamer worsens metabolic acidosis in hemodialysis patients. De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432 [TBL] [Abstract][Full Text] [Related]
28. Introduction to sevelamer hydrochloride and its clinical effects. Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137 [TBL] [Abstract][Full Text] [Related]
29. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Almirall J; Veciana L; Llibre J Am J Nephrol; 1994; 14(3):192-6. PubMed ID: 7977479 [TBL] [Abstract][Full Text] [Related]
30. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142 [TBL] [Abstract][Full Text] [Related]
31. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Block GA Clin Nephrol; 2000 Oct; 54(4):318-24. PubMed ID: 11076108 [TBL] [Abstract][Full Text] [Related]
32. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C; J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233 [TBL] [Abstract][Full Text] [Related]
33. [Changes of calcium-phosphorus metabolism in patients with chronic renal failure on hemodialysis treatment]. Pérez Ruilópez MA; Damiano Rivero A; Herrerías Echabe JM; Garrido Peralta M Rev Iber Endocrinol; 1976; 23(138):535-55. PubMed ID: 1013577 [TBL] [Abstract][Full Text] [Related]
34. Successful management of hypoparathyroidism following total thyroidectomy with vitamin D(3) alone. Suzuki M; Tsunoda A; Kudo T; Okada R; Toyoda M Auris Nasus Larynx; 2014 Feb; 41(1):53-5. PubMed ID: 23727329 [TBL] [Abstract][Full Text] [Related]
35. Oral vitamin D or calcium carbonate in the prevention of renal bone disease? Argilés A; Mourad G; Mion C Curr Opin Nephrol Hypertens; 1996 Jul; 5(4):329-36. PubMed ID: 8823530 [TBL] [Abstract][Full Text] [Related]
36. The absorption of dietary phosphorus and calcium in hemodialysis patients. Ramirez JA; Emmett M; White MG; Fathi N; Santa Ana CA; Morawski SG; Fordtran JS Kidney Int; 1986 Nov; 30(5):753-9. PubMed ID: 3784305 [TBL] [Abstract][Full Text] [Related]
37. [Use of calcium carbonate as an intestinal chelator of phosphorus]. Bongiorno P; Caligaris F; Montalcini G; Biamino E; Imarisio P; Dagna L; Arnaud A Minerva Urol Nefrol; 1990; 42(1):55-7. PubMed ID: 2389224 [TBL] [Abstract][Full Text] [Related]